Article
Cell Biology
Fan Yang, Xuguang Zhang, Feifei Hu, Ye Yu, Lei Luo, Xuan Deng, Yuzheng Zhao, Bo Pan, Jinping Zheng, Yugang Qiu, Jun Guo, Feng Xiao, Xiaomei Xie, Zhenyu Ju, Yong Zhou
Summary: This study examined the association between NAD(+) levels and anemia in women. The findings showed that higher NAD(+) levels were significantly associated with a lower prevalence of anemia, particularly microcytic anemia and normocytic anemia.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2022)
Article
Hematology
Vinzon Ibanez, Kestis Vaitkus, Xu Zhang, Jagadeesh Ramasamy, Angela E. Rivers, Yogen Saunthararajah, Robert Molokie, Donald Lavelle
Summary: Increased levels of fetal hemoglobin (HbF) can alleviate the symptoms of sickle cell disease (SCD) and improve patients' lifespan. The use of pharmacological agents that increase HbF offers the best potential for disease intervention. Combining inhibitors of DNA methyltransferase (DNMT1) and lysine-specific demethylase 1A (LSD1) can synergistically increase HbF, providing a promising strategy for the treatment of SCD.
Article
Medicine, Research & Experimental
Sanne J. C. M. Frambach, Ria de Haas, Jan A. M. Smeitink, Frans G. M. Russel, Tom J. J. Schirris
Summary: Stimulation of PPARα and LXRα pathways can attenuate the increased NAD(P)H levels in CI-deficient cells, suggesting a potential therapeutic approach for CI deficiency.
Article
Multidisciplinary Sciences
Martin Rodriguez, Brady Trevisan, Ritu M. Ramamurthy, Sunil K. George, Jonathan Diaz, Jordan Alexander, Diane Meares, Denise J. Schwahn, David R. Quilici, Jorge Figueroa, Michael Gautreaux, Andrew Farland, Anthony Atala, Christopher B. Doering, H. Trent Spencer, Christopher D. Porada, Graca Almeida-Porada
Summary: Hemophilia A is a common X-linked bleeding disorder with severe cases having very low FVIII levels leading to spontaneous and life-threatening bleeds. Researchers showed that prenatal transplantation of bioengineered human placental cells in sheep fetuses significantly increased FVIII levels for more than 3 years without triggering immune responses. This study demonstrates the feasibility and safety of treating hemophilia A before birth.
NATURE COMMUNICATIONS
(2023)
Article
Pediatrics
Amelia E. Gavulic, Danielle Dougherty, Shih-Hon Li, Alissa R. Carver, Jennifer R. Bermick, George B. Mychaliska, Ronald B. Hirschl, Erin E. Perrone
Summary: The study found that fetal hemoglobin concentrations in ELGANs decrease significantly after transfusion with adult donor pRBCs, and although levels may increase if no additional transfusions are given, they still remain lower than expected. Further research is needed to determine the benefits of maintaining higher fetal hemoglobin concentrations in these patients and evaluate the potential improvement in patient outcomes if HbF is administered instead of adult donor pRBCs.
JOURNAL OF PEDIATRIC SURGERY
(2021)
Article
Biology
Nithin Sam Ravi, Beeke Wienert, Stacia K. Wyman, Henry William Bell, Anila George, Gokulnath Mahalingam, Jonathan T. Vu, Kirti Prasad, Bhanu Prasad Bandlamudi, Nivedhitha Devaraju, Vignesh Rajendiran, Nazar Syedbasha, Aswin Anand Pai, Yukio Nakamura, Ryo Kurita, Muthuraman Narayanasamy, Poonkuzhali Balasubramanian, Saravanabhavan Thangavel, Srujan Marepally, Shaji R. Velayudhan, Alok Srivastava, Mark A. DeWitt, Merlin Crossley, Jacob E. Corn, Kumarasamypet M. Mohankumar
Summary: Inspired by naturally occurring point mutations in sickle cell patients, this study used base editing to identify novel regulatory regions in the HBG promoter and successfully upregulated fetal hemoglobin synthesis.
Review
Medicine, General & Internal
Siti Nur Nabeela A'ifah Mohammad, Salfarina Iberahim, Wan Suriana Wan Ab Rahman, Mohd Nazri Hassan, Hisham Atan Edinur, Maryam Azlan, Zefarina Zulkafli
Summary: Anemia, characterized by decreased oxygen transport due to low red blood cells or hemoglobin levels, can cause fatigue and weakness in individuals. It can be hereditary or acquired, with strategies like increasing fetal hemoglobin helping to alleviate symptoms.
Review
Pharmacology & Pharmacy
Rahyssa Rodrigues Sales, Barbara Lisboa Nogueira, Jessica Abdo Goncalves Tosatti, Karina Braga Gomes, Marcelo Rizzatti Luizon
Summary: Hydroxyurea is commonly used for the treatment of sickle cell anemia (SCA), but there is variability in patient response. This systematic review explores the impact of genetic polymorphisms on HbF levels in SCA patients treated with hydroxyurea, and identifies SNPs and genes associated with HbF changes. The findings suggest that changes in HbF levels upon hydroxyurea therapy are likely regulated by multiple loci.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Ryohei Takeishi, Tomofumi Misaka, Yasuhiro Ichijo, Shinji Ishibashi, Mitsuko Matsuda, Yukio Yamadera, Himika Ohara, Yukiko Sugawara, Yu Hotsuki, Koichiro Watanabe, Fumiya Anzai, Yu Sato, Takamasa Sato, Masayoshi Oikawa, Atsushi Kobayashi, Takayoshi Yamaki, Kazuhiko Nakazato, Akiomi Yoshihisa, Yasuchika Takeishi
Summary: Selenoprotein P derived from the liver is associated with hepatic hypoperfusion and may serve as a novel target for cardiohepatic interactions and a useful biomarker for predicting prognosis in patients with heart failure.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Neurosciences
Yian Gao, Chaofan Sui, Boyao Chen, Haotian Xin, Yena Che, Xinyue Zhang, Na Wang, Yuanyuan Wang, Changhu Liang
Summary: Emerging evidence suggests that type 2 diabetes mellitus (T2DM) is associated with decreased gray matter volume (GMV) and tau hyperphosphorylation. Insulin resistance is one of the mechanisms that lead to neuronal degeneration in T2DM. This study aims to investigate the association between GMV and serum tau protein phosphorylated at threonine 181 (P-tau-181) in T2DM patients. The results showed that T2DM patients with high and normal glycosylated hemoglobin levels both had significantly decreased GMV. Additionally, serum P-tau-181 levels were correlated with GMV in specific brain regions.
FRONTIERS IN NEUROSCIENCE
(2023)
Article
Hematology
Poonam Tripathi, Sarita Agarwal, Kausik Mandal, Anshul Gupta, Aditya Narayan Sarangi
Summary: This study aimed to evaluate the impact of genetic polymorphisms in QTL genes on HbF levels in beta thalassemia major patients. The study found a positive correlation between the polymorphisms in BCL11A and HBS1L-MYB genes and HbF levels. Further research with a larger sample size and other modifier genes is needed to validate the results.
THALASSEMIA REPORTS
(2023)
Article
Oncology
Joshua F. Zeidner, Daniel J. Lee, Mark Frattini, Gil D. Fine, Judy Costas, Kathryn Kolibaba, Stephen P. Anthony, David Bearss, B. Douglas Smith
Summary: Alvocidib, when combined with 7+3 induction therapy, shows promising clinical activity in newly diagnosed acute myeloid leukemia patients, indicating the potential for further investigation of Alvocidib combinations in this population.
CLINICAL CANCER RESEARCH
(2021)
Letter
Oncology
Sutapa Sinha, Charla R. Secreto, Justin C. Boysen, Connie Lesnick, Zhiquan Wang, Wei Ding, Timothy G. Call, Saad J. Kenderian, Sameer A. Parikh, Steven L. Warner, David J. Bearss, Asish K. Ghosh, Neil E. Kay
BLOOD CANCER JOURNAL
(2021)
Article
Multidisciplinary Sciences
Tsz-Yin Chan, Christina M. Egbert, Julia E. Maxson, Adam Siddiqui, Logan J. Larsen, Kristina Kohler, Eranga Roshan Balasooriya, Katie L. Pennington, Tsz-Ming Tsang, Madison Frey, Erik J. Soderblom, Huimin Geng, Markus Muschen, Tetyana V. Forostyan, Savannah Free, Gaelle Mercenne, Courtney J. Banks, Jonard Valdoz, Clifford J. Whatcott, Jason M. Foulks, David J. Bearss, Thomas O'Hare, David C. S. Huang, Kenneth A. Christensen, James Moody, Steven L. Warner, Jeffrey W. Tyner, Joshua L. Andersen
Summary: TNK1, a non-receptor tyrosine kinase, has been found to play a key role in cancer by toggling between inactive states involving interaction with 14-3-3 and active states through ubiquitin binding. The discovery of a TNK1 inhibitor, TP-5801, highlights its potential as a therapeutic target for TNK1-transformed cells and tumor growth suppression in vivo.
NATURE COMMUNICATIONS
(2021)
Letter
Oncology
Joshua F. Zeidner, Tara L. Lin, Carlos E. Vigil, Gil Fine, M. Yair Levy, Aziz Nazha, Jordi Esteve, Daniel J. Lee, Karen Yee, Andrew Dalovisio, Eunice S. Wang, Juan M. Bergua Burgues, Jeffrey Schriber, Mark R. Litzow, Olga Frankfurt, Teresa Bernal Del Castillo, Vijaya Raj Bhatt, Bhavana Bhatnagar, Priyanka Mehta, Richard Dillon, Maria Vidriales Vicente, Stephen Anthony, David Bearss, Pau Montesinos, B. Douglas Smith
BLOOD CANCER JOURNAL
(2021)
Meeting Abstract
Oncology
Hariprasad Vankayalapati, Kyle Medley, Zhaoliang Li, Dongqing Yan, David Bearss, Alana Welm
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Meeting Abstract
Oncology
Lan Phi, Takashi Semba, Jason Foulks, Steven Warner, David Bearss, Savitri Krishnamurthy, James Long, James Reuben, Debu Tripathy, Naoto Ueno, Xiaoping Wang
Meeting Abstract
Oncology
Salah Sommakia, Satya Pathi, Yuta Matsumura, Curtis Allred, Ethika Tyagi, Matthew Lalonde, Jason Foulks, Adam Siddiqui, Clifford Whatcott, David Bearss, Steven Warner
Meeting Abstract
Oncology
Yuta Matsumura, Ethika Tyagi, Satya Pathi, Dan D. Vo, Tianxiang Zhu, Suman Verma, Clifford J. Whatcott, Stephen P. Anthony, Adam Siddiqui, Jason M. Foulks, David J. Bearss, Steven L. Warner
Meeting Abstract
Oncology
Tsz-Yin Chan, Christina Egbert, Logan Larsen, Jeremy Tsang, Julia Maxson, Eranga Roshan, Clifford J. Whatcott, Kim Wontak, Gaelle Mercenne, Savannah Free, Adam Siddiqui, Tetyana Forostyan, Ethika Tyagi, Kenneth A. Christensen, David J. Bearss, James Moody, Jeffrey Tyner, Jason M. Foulks, Steven L. Warner, Joshua Lyon Andersen
Meeting Abstract
Oncology
Tetyana V. Forostyan, Ethika Tyagi, Jason M. Foulks, Matthew Lalonde, Joshua L. Andersen, Adam Siddiqui, Clifford J. Whatcott, David Bearss, Steve Warner
